Compare FA & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FA | TLX |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | Australia |
| Employees | N/A | 1184 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.5B |
| IPO Year | 2021 | N/A |
| Metric | FA | TLX |
|---|---|---|
| Price | $19.64 | $10.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $15.67 | ★ $21.13 |
| AVG Volume (30 Days) | ★ 2.0M | 146.1K |
| Earning Date | 05-07-2026 | 08-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.97 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $1,574,389,000.00 | N/A |
| Revenue This Year | $8.42 | N/A |
| Revenue Next Year | $7.26 | N/A |
| P/E Ratio | $1,918.00 | ★ $150.33 |
| Revenue Growth | ★ 83.02 | N/A |
| 52 Week Low | $8.82 | $6.28 |
| 52 Week High | $22.78 | $14.27 |
| Indicator | FA | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 52.21 | 43.37 |
| Support Level | $13.97 | $10.12 |
| Resistance Level | $20.97 | $11.38 |
| Average True Range (ATR) | 0.90 | 0.26 |
| MACD | -0.28 | -0.16 |
| Stochastic Oscillator | 16.20 | 3.74 |
First Advantage Corp is a provider of software and data in the Human Resources technology industry. The company provides end-to-end identity solutions, criminal background screening, credential verifications, drug and health screening, and continuous risk monitoring. It combines AI-powered proprietary technology platforms with proprietary data, primary source data, and third-party data. Its reportable segments are First Advantage Americas, First Advantage International, and Sterling. The company generates maximum revenue from the Sterling segment, which provides similar services as compared to First Advantage's Americas and International segments on a global basis. Geographically, the company generates the majority of its revenue from the United States.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.